Bleeding complications of unfractionated heparin

Expert Opinion on Drug Safety

Volumn 10, Issue 1, 2011, Pages 77-84

  Krishnaswamy, Amar ^a   Lincoff, A Michael ^a   Cannon, Christopher P ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

anticoagulation; autohep; bleeding classification; heparin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; HIRULOG; PLACEBO; PRASUGREL; STREPTOKINASE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADD ON THERAPY; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CARDIAC PATIENT; CORONARY ARTERY BYPASS GRAFT; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FIBRINOLYTIC THERAPY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; PARTIAL THROMBOPLASTIN TIME; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; HEMORRHAGE; HEPARIN; HUMANS; TREATMENT OUTCOME;

EID: 78650454652     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.521150     Document Type: Review

References (38)

1. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:188S-203S (Pubitemid 39297954)
2. Melloni C, Alexander KP, Chen AY, et al. Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. Am Heart J 2008;156:209-15
3. Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006;114:774-82 (Pubitemid 44268228)
4. Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol 2000;111:397-406
5. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-9 (Pubitemid 23286474)
6. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287:324-7
7. Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991;151:333-7
8. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589-95
9. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993;119:874-81
10. Hochman JS, Wali AU, Gavrila D, et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J 1999;138:313-18 (Pubitemid 29379684)
11. Becker RC, Ball SP, Eisenberg P, et al. A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators. Am Heart J 1999;137:59-71 (Pubitemid 29038363)
12. Anand SS, Yusuf S, Pogue J, et al. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003;107:2884-8 (Pubitemid 36736627)
13. Cheng S, Morrow DA, Sloan S, et al. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Circulation 2009;119:1195-202
14. Nallamothu BK, Bates ER, Hochman JS, et al. Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. Eur Heart J 2005;26:1506-12
15. Newby LK, Harrington RA, Bhapkar MV, et al. An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. J Thromb Thrombolysis 2002;14:33-42
16. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996;94:911-21 (Pubitemid 26292840)
17. Krishnaswamy A, Lincoff AM, Cannon CP. The use and limitations of unfractionated heparin. Crit Pathw Cardiol 2010;9:35-40
18. Menon V, Berkowitz SD, Antman EM, et al. New heparin dosing recommendations for patients with acute coronary syndromes. Am J Med 2001;110:641-50 (Pubitemid 32510692)
19. Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996;93(5):870-8 (Pubitemid 126425250)
20. Bonello L, de Labriolle A, Roy P, et al. Head-to-head comparison of bivalirudin versus heparin without glycoprotein IIb/IIIa inhibitors in patients with acute myocardial infarction undergoing primary angioplasty. Cardiovasc Revasc Med 2009;10:156-61
21. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82
22. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54 (Pubitemid 38923793)
23. Rao SV, OGrady K, Pieper KS, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 2006;47:809-16
24. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30 (Pubitemid 351724451)
25. Serebruany VL, Atar D. Assessment of bleeding events in clinical trials-proposal of a new classification. Am J Cardiol 2007;99:288-90 (Pubitemid 46072771)
26. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005;294:3108-16 (Pubitemid 43016802)
27. Wang TY, Chen AY, Alexander KP, et al. Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. Am J Med 2008;121:805-10
28. Spinler SA, Mahaffey KW, Gallup D, et al. Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. Int J Cardiol 2009. [Epub ahead of print]
29. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502 (Pubitemid 32758501)
30. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15 (Pubitemid 350106708)
31. Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008;359:688-96
32. Rao SV, Jollis JG, Harrington RA, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004;292:1555-62 (Pubitemid 39314961)
33. Sabatine MS, Morrow DA, Giugliano RP, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 2005;111:2042-9 (Pubitemid 40577898)
34. Perrotta PL, Snyder EL. Non-infectious complications of transfusion therapy. Blood Rev 2001;15:69-83
35. Becker RC, Cyr J, Corrao JM, Ball SP. Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: a coronary care unit experience. Am Heart J 1994;128:719-23 (Pubitemid 24314660)
36. Zabel KM, Granger CB, Becker RC, et al. Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. Am Heart J 1998;136:868-76
37. Cannon CP, Dingemanse J, Kleinbloesem CH, et al. Automated heparin-delivery system to control activated partial thromboplastin time: evaluation in normal volunteers. Circulation 1999;99:751-6 (Pubitemid 29083014)
38. Hicks JM, Haeckel R, Price CP, et al. Recommendations and opinions for the use of point-of-care testing for hospitals and primary care: summary of a 1999 symposium. Clin Chim Acta 2001;303:1-17 (Pubitemid 32121800)